The aim of the research was to investigate prognostic factors in patients with resected colorectal liver metastases (CLMs) after biological and chemotherapy, which made initially unresectable disease suitable for resection. Sixty-six patients with resected CLMs, operated after induction bio-chemotherapy with bevacizumab + FOLFOX4, treated at the Clinic of Oncology, Clinical Center Niš from 2010 - 2017 were included. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test according to demographic characteristics, characteristics of the disease and the treatment. A univariate COX regression analysis was performed. In patients with up to 4 CLMs, DFS was significantly longer than in patients with five or more metastases (18,384 v.s. 6,85 months; p < 0,001). Significantly longer OS was present in patients with up to four CLMs than in those with five or more CLMs (44,687 v.s. 29,723 months; p=0,006) and in patients without extrahepatic disease (41,71 v.s. 23,283 months; p=0,012). In the univariate analysis, five or more CLMs were predictors of poorer DFS (HR 3,989; 95% CI 1,055 - 15,087; p = 0,042), whereas the absence of extrahepatic disease was a predictor of better OS (HR 0,122; 95% CI 0,017 - 0,869; p = 0,036). Results of this research are in concordance with previous larger studies in patients with resected CLMs. The number of hepatic and the presence of extrahepatic metastases are prognostic parameters in patients with resected CLM after conversion bio-chemotherapy.

The aim of this study was to define predictive factors for the therapy response and early recurrence after hepatectomy in patients that received conversion therapy FOLFOX4 and bevacizumab for colorectal liver metastases. This observational retrospective single center analysis included sixty-five patients treated with bevacizumab and FOLFOX4 regimen for potentially resectable colorectal liver metastases. Patients were divided in groups based on objective therapeutic response. Groups with early (≤ 3 months) and late recurrence (≥ 12 months) after hepatectomy were selected. Disease characteristics among groups were compared as well as univariate and multivariate analysis. Independent risk factor for the lack of therapy response was rectal localization (OR 3.86 [95% CI 1.31-11.34]; p = 0.014). Left colon cancer was independent protective factor for the response absence (OR 0.205 [95% CI 0.05-0.80]; p = 0.022). Independent predictive factors for early recurrence were synchronous liver disease (OR 18 [95%CI 2.47-131.28]; p = 0.004) and the number of metastases (OR 2.42 [95% CI 1.14-5.01]; p = 0.021). In multivariate model only synchronous liver metastases had statistical significance (OR 13.79 [95% CI 1.54-123.77]; p = 0.019). Left colon cancer was predictor of response to therapy with bevacizumab and FOLFOX4 and rectal localization was indicative of response absence. Independent risk factors for early recurrence were the number of metastases and synchronous liver involvement.

No abstract

Peripheral T/NK-cell lymphomas (PTCL) are rare, bizarre, and extremely diverse cancers. The disease is prone to relapse with a high level of chemorefractoriness leading to a poor outcome. Almost 70% of patients will experience relapse, with a median 5-year overall survival (OS) in approximately 30%. Upfront management of PTCL has been extrapolated from the treatment paradigm for aggressive B-NHL. However, universally accepted induction is rather palliative than curative. Regardless of the maximal reinforcement of upfront management, only event-free survival has been influenced but not the OS. All actual guidelines emphasize the importance of the autologous stem cell transplantation (auto-SCT) as a consolidation of first major response. The allogeneic SCT (allo-SCT) is not evidence-based part of upfront management. Nevertheless, its use is justified in the relapsed/refractory setting. Unfortunately, the vast majority of patients are not candidates for aggressive treatment modalities making the recommended paradigm as limited feasible. Regarding such a situation, novel compounds are warranted. Although presented data indicate ominous prognosis in PTCL, it is important to denote that there has been evidence-based improvement in the treatment paradigm by the introduction of L-Asparaginase and targeted therapy for CD30+ PTCL. In this sense, a considerable number of new compounds entered early phase trials and gave promising results. All lights have been focused on upcoming results given the fact that at the moment we have not much to offer to the patients who have relapsed or were primary refractory.

Introduction Recommended biological agents for the first line treatment of left-sided metastatic colorectal cancer (mCRC) without mutations in RAS/BRAF genes is cetuximab or panitumumab, while for right-sided mCRC bevacizumab is advised instead. For transversal colon mCRC the data about biological treatment efficacy is lacking. We present a patient with right-sided mCRC originated from transversal colon where panitumumab and chemotherapy treatment resulted in great outcome. Case outline A 56-year-old woman was diagnosed with transversal colon adenocarcinoma, without RAS genes mutations, with multiple liver metastases disseminated in both lobes. After the operation of primary tumour, the patient was treated with panitumumab and FOLFOX4 chemotherapy regimen. After 2 months of treatment, the dramatic response was evident, sum of diameter of target lesions decreased for 70.5%. After 2 more months of therapy, further decrease for 22.5% was evident. Liver metastases were operated on. Histopathology revealed fibrotic and necrotic tissue in all suspicious lesions, except in one focus where adenocarcinoma was found, but with 90% of surrounding necrosis. Twelve months after liver surgery the patient is without signs of progressive disease. Conclusion Detailed comprehensive studies of genetic features of mCRC hold a key to personalized treatment options and better outcomes for patients with mCRC.